Overview

Innoviva (NASDAQ: INVA) is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva’s portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK.

Royalties Earned

chart

Press Releases

Date Title and Summary
Toggle Summary Theravance and GlaxoSmithKline Form Alliance to Develop Next-Generation Respiratory Medicines
Theravance and GlaxoSmithKline Form Alliance to Develop Next-Generation Respiratory Medicines SOUTH SAN FRANCISCO, CA and LONDON, UK Date: January 6, 2003 Theravance, Inc. and GlaxoSmithKline plc (LSE & NYSE: GSK) announced today that they have formed an alliance to develop and commercialize novel
Toggle Summary Theravance Announces Promising Results From Multiple Research And Clinical Studies With the Investigational Antibiotic TD-6424
Phase 2 Trials Underway For Serious Infections Caused by Gram-Positive Bacteria
Toggle Summary Theravance Announces Data on Novel Anesthesia Program
Theravance Announces Data on Novel Anesthesia Program SOUTH SAN FRANCISCO, Calif., November 24, 2003 /PRNewswire/ -- Theravance, Inc., today announced that results from a study with its investigational intravenous pharmacokinetically-responsive sedative hypnotic THRX-918661 were recently presented
Toggle Summary Theravance Announces Positive Phase 2 Results for Once-Daily Beta2-Agonists in Development for Asthma and COPD
Theravance Announces Positive Phase 2 Results for Once-Daily Beta2-Agonists in Development for Asthma and COPD SOUTH SAN FRANCISCO, CA December 3, 2003/ PR Newswire/ -- Theravance, Inc. announced today that the lead compounds in its alliance with GlaxoSmithKline (GSK) to identify new long-acting,
Presentations & Events
There are currently no events to display.

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.